04/01/1999
Current Effective Date:
01/01/2015
The Food and Drug Administration (FDA) approved OncoScint™ CR/OV-In (indium IN 111 satumomab pendetide) as a diagnostic imaging agent for determining the extent and location of extrahepatic malignant disease in patients with known colorectal or ovarian cancer.
HMSA follows the FDA-approved indications and guidelines in providing benefit coverage. HMSA's Plan for QUEST Integration Members provides benefits for two full post-infusion body scans performed during a single session per a patient's lifetime. OncoScint is not covered as a screening test for ovarian or colorectal cancer.
Claims Filing Information
Please use the applicable procedure codes.
| CPT Code | Description |
|---|---|
| 78802 | Radionuclide localization of tumor, whole body |
| 78803 | Tumor localization (SPECT) |
Revision History
| Date | Nature of Revision |
|---|---|
| 08/03/2026 | Migrated to new platform. |